Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.72 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.72 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27071719 | 0.88 | DDB1 (0.57) | CRBNDDB1HRH4HRH3 | |
| SCHEMBL23551579 | 0.84 | CRBN (0.77) | CRBNDDB1 | |
| SCHEMBL26621484 | 0.84 | CRBN (1.00) | CRBNDDB1 | |
| SCHEMBL22119593 | 0.83 | CRBN (0.76) | CRBNDDB1 | |
| SCHEMBL24126163 | 0.83 | CRBN (0.76) | CRBNDDB1 | |
| SCHEMBL29640977 | 0.83 | CRBN (0.76) | CRBNDDB1 | |
| SCHEMBL29946918 | 0.81 | CRBN (0.72) | CRBNDDB1 | |
| SCHEMBL25122073 | 0.81 | CRBN (0.72) | CRBNDDB1HRH4HRH3 | |
| SCHEMBL30774975 | 0.81 | CRBN (0.72) | CRBNDDB1 | |
| SCHEMBL27034416 | 0.81 | CRBN (0.72) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2023083194-A1 | WEE1 PROTEIN KINASE DEGRADATION AGENT AND USE THEREOF | 杭州格博生物医药有限公司 | 2023-05-19 | — | — | WO | disclosed |
| WO-2023072270-A1 | PROTAC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | 百极弘烨(南通)医药科技有限公司 | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | BCL6, BCL6B, BCL3 | CRBN 91/4885DDB1 280/4885HRH4 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.